Fulcrum Therapeutics’ Losmapimod Receives the US FDA’s Fast Track Designation to Treat Facioscapulohumeral Muscular Dystrophy

 Fulcrum Therapeutics’ Losmapimod Receives the US FDA’s Fast Track Designation to Treat Facioscapulohumeral Muscular Dystrophy

Shots:

  • The US FDA has granted FTD to losmapimod for the treatment of FSHD while the therapy has previously received ODD for FSHD
  • The company will present full data from the P-IIb ReDUX4 trial assessing losmapimod vs PBO in patients with FSHD at FSHD on June 24-25, 2021 that include 1EP results i.e., reduction from baseline of DUX4-driven gene expression and pre-specified sensitivity analysis assessing biopsies with the highest pre-treatment level of DUX4-driven gene expression
  • The additional 2EPs results i.e., disease progression via skeletal muscle MRI, exploratory EPs evaluate muscle function measures and patient-reported outcomes

Click here to­ read full press release/ article | Ref: Fulcrum Therapeutics | Image: Fulcrum Therapeutics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post